No. 2 US House Republican Scalise undergoing further cancer treatment
No. 2 US House Republican Scalise undergoing further cancer treatment By Reuters
Breaking News
‘;
Published Jan 05, 2024 02:32PM ET
Updated Jan 05, 2024 03:25PM ET
© Reuters. U.S. House Republican Majority Leader Steve Scalise (R-LA) faces reporters after House Republicans nominated U.S. Rep. Tom Emmer (R-MN) to be House Speaker at a House Republican conference meeting to choose a nominee at the U.S. Capitol in Washington, U.S
WASHINGTON (Reuters) -U.S. House of Representatives Republican leader Steve Scalise is having a stem cell transplant as part of his treatment for multiple myeloma, a common form of blood cancer, his office said in a statement on Friday.
The Louisiana lawmaker will work remotely from home until he returns to Washington in February, the statement said.
His absence cuts Republicans’ already slim majority even further, meaning House Speaker Mike Johnson will be able to lose just one vote on bills without Democratic support. An additional Republican retirement will cut that to zero later this month.
Scalise, the No. 2-ranking Republican in the House who ran for speaker in October, had a positive response to chemotherapy, which was completed in December, his office said.
Scalise announced the cancer diagnosis in August.
No. 2 US House Republican Scalise undergoing further cancer treatment
Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information
© 2007-2024 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.